Neoadjuvant treatment strategies for hepatocellular carcinoma

Table 2 Summary of pre-transplant transarterial chemoembolization and trans-arterial radioembolization in downstage treatment for hepatocellular carcinoma

Year	Neoadjuvant treatment	Entry criteria	Success downstage rate	Subsequent therapy	Adverse events	Incidence rate	Ref.
2015	Conventional TACE; I131 Metuximab TACE	Patients within USCF criteria	NA	OLT	Hepatic artery thrombosis hepatic aneurysm	1.5%	[89]
2015	DEB-TACE	BCLC 0/A/B stage	26.7%	OLT	Grade 3/4	3.2%	[102]
2017	TACE		NA	OLT	Hepatic artery thrombosisRetransplant	27%22.7%	[90]
2020	DEB-TACE	AJCC stage ≤ T3a	73.3%	OLT	Grade 3Grade 4	3.1%0.0%	[86]
2006	Y-90 RE	UNOS stage T3	66.0%	OLT	NA	NA	[103]
2017	Y-90 RE	BCLC A/B/C stage	78.9%	OLT	NA	NA	[104]
2011	Y-90 RE	UNOS stage T2, T3, T4a	50.0%	OLT	Hyperbilirubinemia (Grade3)	13.0%	[105]
2013	Y-90 RE	UNOS stage T3, T4a	33.0%	OLT	NA	NA	[95]
2021	Y-90 RE	UNOS stage T1, T2, T3, T4	43.0%	OLT	NA	NA	[96]

DEB-TACE: Drug-eluting beads transarterial chemoembolization; TACE: Transarterial chemoembolization; Y-90 RE: Yttrium-90 radioembolization; UCSF: University of California, San Francisco; BCLC: Barcelona Clinic Liver Cancer; AJCC: American Joint Committee on Cancer; UNOS: United Network for Organ Sharing; NA: Not available; I¹³¹: Iodine-131; OLT: Orthotopic liver transplantation.